What is a primary effect of statins on cardiovascular risk?

Statins primarily function by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in the biosynthesis of cholesterol in the liver. As a result of this inhibition, statins lead to a significant decrease in LDL cholesterol levels, which is a major contributor to cardiovascular risk. Lowering LDL cholesterol is associated with the stabilization of atherosclerotic plaques and a reduction in the incidence of cardiovascular events such as heart attacks and strokes. This mechanism underpins the therapeutic use of statins in patients with hyperlipidemia or those at risk for cardiovascular disease, making their primary effect on cardiovascular risk a reduction in LDL cholesterol levels.

The other options do not accurately reflect the primary effects of statins. Statins do not significantly increase HDL cholesterol levels, and rather than promoting platelet aggregation or enhancing inflammatory responses, they actually have stabilizing effects on plaques and can exert anti-inflammatory effects, contributing to their cardiovascular protective qualities.